Nors, J., Iversen, L. H., Erichsen, R., Gotschalck, K. A. & Andersen, C. L. Incidence of recurrence and time to recurrence in stage I to III colorectal cancer: a nationwide Danish cohort study. JAMA Oncol. 10, 54–62 (2024).

Article  PubMed  Google Scholar 

Popat, S., Hubner, R. & Houlston, R. S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23, 609–618 (2005).

Article  CAS  PubMed  Google Scholar 

Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, C. G. et al. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br. J. Cancer 115, 25–33 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alexander, P. G., McMillan, D. C. & Park, J. H. The local inflammatory response in colorectal cancer — type, location or density? A systematic review and meta-analysis. Cancer Treat. Rev. 83, 101949 (2020).

Article  CAS  PubMed  Google Scholar 

Pagès, F. et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet 391, 2128–2139 (2018).

Article  PubMed  Google Scholar 

Williams, C. J. M. et al. Evaluation of CD3 and CD8 T-cell immunohistochemistry for prognostication and prediction of benefit from adjuvant chemotherapy in early-stage colorectal cancer within the QUASAR trial. J. Clin. Oncol. https://doi.org/10.1200/JCO.23.02030 (2024).

Article  PubMed  Google Scholar 

Sinicrope, F. A. et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl Cancer Inst. 103, 863–875 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hutchins, G. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261–1270 (2011).

Article  PubMed  Google Scholar 

Sinicrope, F. A. et al. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. Eur. J. Cancer 144, 101–112 (2021).

Article  CAS  PubMed  Google Scholar 

Cohen, R. et al. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency. Eur. J. Cancer 86, 266–274 (2017).

Article  CAS  PubMed  Google Scholar 

Morton, D. et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J. Clin. Oncol. 41, 1541–1552 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dworak, O., Keilholz, L. & Hoffmann, A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int. J. Colorectal Dis. 12, 19–23 (1997).

Article  CAS  PubMed  Google Scholar 

André, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020).

Article  PubMed  Google Scholar 

Diaz, L. A. Jr. et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23, 659–670 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).

Article  CAS  PubMed  Google Scholar 

Cercek, A. et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N. Engl. J. Med. 386, 2363–2376 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasi, P. M. et al. Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. Oncogene 42, 3252–3259 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Timmermann, B. et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS ONE 5, e15661 (2010).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lenz, H.-J. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J. Clin. Oncol. 40, 161–170 (2022).

Article  CAS  PubMed  Google Scholar 

Lenz, H.-J. et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): expanded efficacy analysis from CheckMate 8HW. J. Clin. Oncol. 42, https://doi.org/10.1200/JCO.2024.42.3_suppl.LBA768 (2024).

Article  PubMed  Google Scholar 

Borràs, D. M. et al. Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer. Cell Discov. 9, 114 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Overman, M. J. et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): checkMate-142 interim results. J. Clin. Oncol. 34, https://doi.org/10.1200/JCO.2016.34.15_suppl.350 (2016).

Article  Google Scholar 

Chen, E. X. et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO.26 study. JAMA Oncol. 6, 831–838 (2020).

Article  PubMed  Google Scholar 

Kawazoe, A. et al. Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III LEAP-017 study. J. Clin. Oncol. 42, 2918–2927 (2024).

Article  CAS  PubMed  Google Scholar 

Eng, C. et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 20, 849–861 (2019).

Article  CAS  PubMed  Google Scholar 

Bullock, A. J. et al. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat. Med. https://doi.org/10.1038/s41591-024-03083-7 (2024).

Article  PubMed  PubMed Central  Google Scholar 

Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482–491 (2010).

Article  CAS  PubMed